Trial Profile
A Phase II Study of Intravenous DX-8951f [exatecan] Administered Daily for Five Days Every Three Weeks to Patients With Advanced or Recurrent Squamous Cell Cancer of the Cervix
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Exatecan (Primary)
- Indications Cervical cancer
- Focus Therapeutic Use
- 25 Oct 2007 Status changed from suspended to completed.
- 11 Sep 2005 New trial record.